

## Lockington, Elliott (SPAC/PSPC)

---

**From:** Media <media@tpsgc-pwgsc.gc.ca>  
**Sent:** April 1, 2020 3:16 PM  
**To:** Harris, Emily (SPAC/PSPC); Roy, Cecely (SPAC/PSPC)  
**Cc:** Media; Jean-François Létourneau; Me'Shel Gulliver Bélanger; Bryan Blom; Elizabeth Lindsay; James Stott  
**Subject:** For MO Approval: Media Response / Tier 1 - COVID-19 and vaccine contracts / Globe and Mail

Emily, Cecely,

For your approval please. [New info.](#)

Merci

Michèle

### **Media response**

#### **Globe and Mail**

#### **Silcoff, Sean (Globe and Mail)**

**Date call received: March-26-20 at 09:17**

**Deadline: March-31-20 at 17:00**

Tier 1 - COVID-19 and vaccine contracts

**CONTEXT** (for your information): The reporter is looking for some information on the Canadian government's influenza and pandemic vaccine procurement contracts. We are also consulting with PHAC for their contribution in our response.

**VALUE STATEMENT:** PSPC is committed to open, fair and transparent procurement processes while obtaining the best possible value for the Government and Canadians.

### **QUESTIONS AND ANSWERS**

#### **Q1. About the contracts:**

##### **A) What do the contracts cover?**

##### **B) What is the status of them, including who has the contracts, when were they awarded, their value and when they expire?**

**A1-2.** [Canada has two manufacturers under contract to supply Pandemic Influenza Vaccine on an "as and when required" basis:](#)

- GlaxoSmithKline Inc. (GSK), which was awarded a [10-year contract](#) in 2011 as Canada's primary supplier;

- Seqirus Canada Inc., which was awarded a [3-year contract](#) in March 2019 as Canada's back-up supplier.

[Both contracts require the supplier to have and maintain sufficient supplies, which means that, in the event of an influenza pandemic, they should be able to produce and supply a vaccine that meets the](#)

influenza vaccines criteria of the World Health Organization (WHO) and European Medicines Agency (EMA).

GSK's contract also includes a portion of Canada's Annual Influenza Vaccine supply.

**Q2. I believe GSK has the 10-year main contract, expiring on March 31, 2021, and there is at least one other to cover secondary/redundancy production, according to [this 2011 press release](#). Given that this main contract expires in just over a year,**

**A) When will the government be putting out the tender for that contract (as well as the secondary contract/s)?**

Under the provisions of the contract, Canada has the option to extend GSK agreement for an additional period of one year and will exercise this option. This means GSK and Seqirus will be under contract as Canada's primary and back-up Pandemic Influenza Vaccine suppliers, respectively, until March 31, 2022.

**B) What will be the expected terms/criteria? If those aren't known yet, what is the likely or expected timeline to publish the tender and pick the successful candidate, based on standard procurement practices in government?**

Work is currently underway to ensure the next procurement cycle is completed and contracts are in place by March 31, 2022. Contract terms and criteria are currently in development.

**Q3. I would also like to know if the advent of the COVID-19 pandemic will affect the procurement process of influenza and pandemic vaccine procurement contracts.**

**A3.** At this time, it is not anticipated that the COVID-19 pandemic will affect the procurement process for the pandemic influenza vaccine, given that this contract will be extended by one year to March 31, 2022. Significant interdepartmental work is underway to prepare for any eventual COVID-19 vaccine so that Canada is ready.